Role of mitochondrial ROS in the brain: from physiology to neurodegeneration

FEBS Letters

Volumn 592, Issue 5, 2018, Pages 692-702

  Angelova, Plamena R ^a   Abramov, Andrey Y ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

astrocytes; mitochondria; neurodegeneration; neuron; reactive oxygen species

Indexed keywords

IRON; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL LOSS; DEMENTIA; FRIEDREICH ATAXIA; GENE; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; NERVE CELL; NERVE DEGENERATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NONHUMAN; PARKINSON DISEASE; PLA2G6 GENE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; VASCULAR DISEASE; ANIMAL; BRAIN; CELL DEATH; DEGENERATIVE DISEASE; ENERGY METABOLISM; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN; CELL DEATH; ENERGY METABOLISM; HUMANS; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; REACTIVE OXYGEN SPECIES;

EID: 85040745723     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1002/1873-3468.12964     Document Type: Review

References (97)

1. Gandhi S and Abramov AY (2012) Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012, 428010.
2. Votyakova TV and Reynolds IJ (2001) DeltaPsi(m)-Dependent and -independent production of reactive oxygen species by rat brain mitochondria. J Neurochem 79, 266–277.
3. Vinogradov AD and Grivennikova VG (2016) Oxidation of NADH and ROS production by respiratory complex I. Biochim Biophys Acta 1857, 863–871.
4. Kovac S, Angelova PR, Holmstrom KM, Zhang Y, Dinkova-Kostova AT and Abramov AY (2015) Nrf2 regulates ROS production by mitochondria and NADPH oxidase. Biochim Biophys Acta 1850, 794–801.
5. Loschen G, Flohe L and Chance B (1971) Respiratory chain linked H(2)O(2) production in pigeon heart mitochondria. FEBS Lett 18, 261–264.
6. Boveris A, Oshino N and Chance B (1972) The cellular production of hydrogen peroxide. Biochem J 128, 617–630.
7. Loschen G, Azzi A, Richter C and Flohe L (1974) Superoxide radicals as precursors of mitochondrial hydrogen peroxide. FEBS Lett 42, 68–72.
8. Gibson GE, Blass JP, Beal MF and Bunik V (2005) The alpha-ketoglutarate-dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration. Mol Neurobiol 31, 43–63.
9. Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS and Beal MF (2004) Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci 24, 7779–7788.
10. Forman HJ, Maiorino M and Ursini F (2010) Signaling functions of reactive oxygen species. Biochemistry 49, 835–842.
11. Mukherjee SP and Mukherjee C (1982) Similar activities of nerve growth factor and its homologue proinsulin in intracellular hydrogen peroxide production and metabolism in adipocytes. Transmembrane signalling relative to insulin-mimicking cellular effects. Biochem Pharmacol 31, 3163–3172.
12. Wardman P and Candeias LP (1996) Fenton chemistry: an introduction. Radiat Res 145, 523–531.
13. Vaarmann A, Gandhi S and Abramov AY (2010) Dopamine induces Ca2+ signaling in astrocytes through reactive oxygen species generated by monoamine oxidase. J Biol Chem 285, 25018–25023.
14. Domijan AM, Kovac S and Abramov AY (2014) Lipid peroxidation is essential for phospholipase C activity and the inositol-trisphosphate-related Ca(2)(+) signal. J Cell Sci 127, 21–26.
15. Angelova PR and Abramov AY (2016) Functional role of mitochondrial reactive oxygen species in physiology. Free Radic Biol Med 100, 81–85.
16. Abramov AY, Scorziello A and Duchen MR (2007) Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. J Neurosci 27, 1129–1138.
17. Angelova PR, Kasymov V, Christie I, Sheikhbahaei S, Turovsky E, Marina N, Korsak A, Zwicker J, Teschemacher AG, Ackland GL et al. (2015) Functional Oxygen Sensitivity of Astrocytes. J Neurosci 35, 10460–10473.
18. Dong Z, Shanmughapriya S, Tomar D, Siddiqui N, Lynch S, Nemani N, Breves SL, Zhang X, Tripathi A, Palaniappan P et al. (2017) Mitochondrial Ca2+ Uniporter Is a Mitochondrial Luminal Redox Sensor that Augments MCU Channel Activity. Mol Cell 65, 1014–1028.
19. Diebold L and Chandel NS (2016) Mitochondrial ROS regulation of proliferating cells. Free Radic Biol Med 100, 86–93.
20. Bras J, Singleton A, Cookson MR and Hardy J (2008) Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS J 275, 5767–5773.
21. Hardy J (2017) The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the “amyloid cascade hypothesis”. FEBS J 284, 1040–1044.
22. Vossius C, Nilsen OB and Larsen JP (2009) Parkinson's disease and nursing home placement: the economic impact of the need for care. Eur J Neurol 16, 194–200.
23. Angelova PR and Abramov AY (2017) Alpha-synuclein and beta-amyloid - different targets, same players: calcium, free radicals and mitochondria in the mechanism of neurodegeneration. Biochem Biophys Res Commun 483, 1110–1115.
24. Abramov AY, Berezhnov AV, Fedotova EI, Zinchenko VP and Dolgacheva LP (2017) Interaction of misfolded proteins and mitochondria in neurodegenerative disorders. Biochem Soc Trans pii: BST20170024.
25. Sheehan JP, Swerdlow RH, Miller SW, Davis RE, Parks JK, Parker WD and Tuttle JB (1997) Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci 17, 4612–4622.
26. Du H, Guo L, Yan S, Sosunov AA, McKhann GM and Yan SS (2010) Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 107, 18670–18675.
27. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G and Yan SD (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19, 2040–2041.
28. Casley CS, Canevari L, Land JM, Clark JB and Sharpe MA (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80, 91–100.
29. Canevari L, Clark JB and Bates TE (1999) beta-Amyloid fragment 25–35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett 457, 131–134.
30. Yu F, Gong P, Hu Z, Qiu Y, Cui Y, Gao X, Chen H and Li J (2015) Cu(II) enhances the effect of Alzheimer's amyloid-beta peptide on microglial activation. J Neuroinflammation 12, 122.
31. Aminzadeh M, Roghani M, Sarfallah A and Riazi GH (2017) TRPM2 dependence of ROS-induced NLRP3 activation in Alzheimer's disease. Int Immunopharmacol 54, 78–85.
32. Ma T, Hoeffer CA, Wong H, Massaad CA, Zhou P, Iadecola C, Murphy MP, Pautler RG and Klann E (2011) Amyloid beta-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J Neurosci 31, 5589–5595.
33. McManus MJ, Murphy MP and Franklin JL (2011) The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J Neurosci 31, 15703–15715.
34. Ng LF, Gruber J, Cheah IK, Goo CK, Cheong WF, Shui G, Sit KP, Wenk MR and Halliwell B (2014) The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease. Free Radic Biol Med 71, 390–401.
35. Elharram A, Czegledy NM, Golod M, Milne GL, Pollock E, Bennett BM and Shchepinov MS (2017) Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer's disease. FEBS J 284, 4083–4095.
36. Avetisyan AV, Samokhin AN, Alexandrova IY, Zinovkin RA, Simonyan RA and Bobkova NV (2016) Mitochondrial Dysfunction in Neocortex and Hippocampus of Olfactory Bulbectomized Mice, a Model of Alzheimer's Disease. Biochemistry (Mosc) 81, 615–623.
37. Keller JN, Guo Q, Holtsberg FW, Bruce-Keller AJ and Mattson MP (1998) Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. J Neurosci 18, 4439–4450.
38. Abramov AY and Duchen MR (2005) The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. Philos. Trans R Soc Lond B Biol Sci 360, 2309–2314.
39. Hashimoto Y, Kaneko Y, Tsukamoto E, Frankowski H, Kouyama K, Kita Y, Niikura T, Aiso S, Bredesen DE, Matsuoka M et al. (2004) Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid-beta peptides via p75NTR/PLAIDD. J Neurochem 90, 549–558.
40. Abramov AY, Canevari L and Duchen MR (2004) Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24, 565–575.
41. Abeti R, Abramov AY and Duchen MR (2011) Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain 134, 1658–1672.
42. Narayan P, Holmstrom KM, Kim DH, Whitcomb DJ, Wilson MR, St George-Hyslop P, Wood NW, Dobson CM, Cho K, Abramov AY et al. (2014) Rare individual amyloid-beta oligomers act on astrocytes to initiate neuronal damage. Biochemistry 53, 2442–2453.
43. Abramov AY, Canevari L and Duchen MR (2004) Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture. Biochim Biophys Acta 1742, 81–87.
44. Shevtsova EF, Vinogradova DV, Neganova ME, Avila-Rodriguez M, Ashraf GM, Barreto GE, Bachurin SO and Aliev G (2017) Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer's Disease. CNS Neurol Disord Drug Targets 16, 677–685.
45. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD et al. (2008) Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14, 1097–1105.
46. Esteras N, Rohrer JD, Hardy J, Wray S and Abramov AY (2017) Mitochondrial hyperpolarization in iPSC-derived neurons from patients of FTDP-17 with 10+16 MAPT mutation leads to oxidative stress and neurodegeneration. Redox Biol 12, 410–422.
47. Liu H and Zhang J (2012) Cerebral hypoperfusion and cognitive impairment: the pathogenic role of vascular oxidative stress. Int J Neurosci 122, 494–499.
48. Yadav A, Sunkaria A, Singhal N and Sandhir R (2018) Resveratrol loaded solid lipid nanoparticles attenuate mitochondrial oxidative stress in vascular dementia by activating Nrf2/HO-1 pathway. Neurochem Int 112, 239–254.
49. Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y and Urabe T (2005) Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 36, 2220–2225.
50. Beal MF (2002) Oxidatively modified proteins in aging and disease. Free Radic Biol Med 32, 797–803.
51. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T et al. (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38, 515–517.
52. Gonzalez-Polo RA, Soler G, Rodriguezmartin A, Moran JM and Fuentes JM (2004) Protection against MPP+ neurotoxicity in cerebellar granule cells by antioxidants. Cell Biol Int 28, 373–380.
53. Abramov AY, Smulders-Srinivasan TK, Kirby DM, Acin-Perez R, Enriquez JA, Lightowlers RN, Duchen MR and Turnbull DM (2010) Mechanism of neurodegeneration of neurons with mitochondrial DNA mutations. Brain 133, 797–807.
54. Andrews ZB, Horvath B, Barnstable CJ, Elsworth J, Yang L, Beal MF, Roth RH, Matthews RT and Horvath TL (2005) Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. J Neurosci 25, 184–191.
55. Lev N, Ickowicz D, Barhum Y, Melamed E and Offen D (2009) DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS. J Mol Neurosci 38, 94–102.
56. Li HM, Niki T, Taira T, Iguchi-Ariga SM and Ariga H (2005) Association of DJ-1 with chaperones and enhanced association and colocalization with mitochondrial Hsp70 by oxidative stress. Free Radic Res 39, 1091–1099.
57. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT and Surmeier DJ (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696–700.
58. Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, Klupsch K, Downward J, Latchman DS, Tabrizi SJ, Wood NW et al. (2009) PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 33, 627–638.
59. Piccoli C, Sardanelli A, Scrima R, Ripoli M, Quarato G, D'Aprile A, Bellomo F, Scacco S, De MG, Filla A et al. (2008) Mitochondrial respiratory dysfunction in familiar parkinsonism associated with PINK1 mutation. Neurochem Res 33, 2565–2574.
60. Abramov AY, Gegg M, Grunewald A, Wood NW, Klein C and Schapira AH (2011) Bioenergetic consequences of PINK1 mutations in Parkinson disease. PLoS One 6, e25622.
61. Hoepken HH, Gispert S, Morales B, Wingerter O, Del TD, Mulsch A, Nussbaum RL, Muller K, Drose S, Brandt U et al. (2007) Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis 25, 401–411.
62. Kostic M, Ludtmann MH, Bading H, Hershfinkel M, Steer E, Chu CT, Abramov AY and Sekler I (2015) PKA Phosphorylation of NCLX Reverses Mitochondrial Calcium Overload and Depolarization, Promoting Survival of PINK1-Deficient Dopaminergic Neurons. Cell Rep 13, 376–386.
63. Deas E, Piipari K, Machhada A, Li A, Gutierrez-del-Arroyo A, Withers DJ, Wood NW and Abramov AY (2014) PINK1 deficiency in beta-cells increases basal insulin secretion and improves glucose tolerance in mice. Open Biol 4, 140051.
64. Dinkova-Kostova AT, Baird L, Holmstrom KM, Meyer CJ and Abramov AY (2015) The spatiotemporal regulation of the Keap1-Nrf2 pathway and its importance in cellular bioenergetics. Biochem Soc Trans 43, 602–610.
65. Gandhi S, Vaarmann A, Yao Z, Duchen MR, Wood NW and Abramov AY (2012) Dopamine induced neurodegeneration in a PINK1 model of Parkinson's disease. PLoS One 7, e37564.
66. Xiao B, Goh JY, Xiao L, Xian H, Lim KL and Liou YC (2017) Reactive oxygen species trigger Parkin/PINK1 pathway-dependent mitophagy by inducing mitochondrial recruitment of Parkin. J Biol Chem 292, 16697–16708.
67. Berger NA, Besson VC, Boulares AH, Burkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL et al. (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 175, 192–222.
68. Delgado-Camprubi M, Esteras N, Soutar MP, Plun-Favreau H and Abramov AY (2017) Deficiency of Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation. Cell Death Differ 24, 120–131.
69. Ludtmann MH, Angelova PR, Ninkina NN, Gandhi S, Buchman VL and Abramov AY (2016) Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase. J Neurosci 36, 10510–10521.
70. Burre J, Vivona S, Diao J, Sharma M, Brunger AT and Sudhof TC (2013) Properties of native brain alpha-synuclein. Nature 498, E4–E6.
71. Nakamura K, Nemani VM, Wallender EK, Kaehlcke K, Ott M and Edwards RH (2008) Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J Neurosci 28, 12305–12317.
72. Reeve AK, Ludtmann MH, Angelova PR, Simcox EM, Horrocks MH, Klenerman D, Gandhi S, Turnbull DM and Abramov AY (2015) Aggregated alpha-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons. Cell Death Dis 6, e1820.
73. Luth ES, Stavrovskaya IG, Bartels T, Kristal BS and Selkoe DJ (2014) Soluble, prefibrillar alpha-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J Biol Chem 289, 21490–21507.
74. Esteves AR, Arduino DM, Swerdlow RH, Oliveira CR and Cardoso SM (2009) Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids. Antioxid Redox Signal 11, 439–448.
75. Deas E, Cremades N, Angelova PR, Ludtmann MH, Yao Z, Chen S, Horrocks MH, Banushi B, Little D, Devine MJ et al. (2016) Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease. Antioxid Redox Signal 24, 376–391.
76. Angelova PR, Horrocks MH, Klenerman D, Gandhi S, Abramov AY and Shchepinov MS (2015) Lipid peroxidation is essential for alpha-synuclein-induced cell death. J Neurochem 133, 582–589.
77. Litvan I, Campbell G, Mangone CA, Verny M, McKee A, Chaudhuri KR, Jellinger K, Pearce RK and D'Olhaberriague L (1997) Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study Brain 120 (Pt 1), 65–74.
78. Angelova PR, Barilani M, Lovejoy C, Dossena M, Vigano M, Seresini A, Piga D, Gandhi S, Pezzoli G, Abramov AY et al. (2018) Mitochondrial dysfunction in Parkinsonian mesenchymal stem cells impairs differentiation. Redox Biol 14, 474–484.
79. Cozzolino M, Pesaresi MG, Gerbino V, Grosskreutz J and Carri MT (2012) Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention. Antioxid Redox Signal 17, 1277–1330.
80. Cozzolino M and Carri MT (2012) Mitochondrial dysfunction in ALS. Prog Neurobiol 97, 54–66.
81. Shaw IC, Fitzmaurice PS, Mitchell JD and Lynch PG (1995) Studies on cellular free radical protection mechanisms in the anterior horn from patients with amyotrophic lateral sclerosis. Neurodegeneration 4, 391–396.
82. Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, Kawaguchi M, Yamamoto T, Sasaki S and Kobayashi M (2001) Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917, 97–104.
83. Shibata N (2001) Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuropathology 21, 82–92.
84. Peixoto PM, Kim HJ, Sider B, Starkov A, Horvath TL and Manfredi G (2013) UCP2 overexpression worsens mitochondrial dysfunction and accelerates disease progression in a mouse model of amyotrophic lateral sclerosis. Mol Cell Neurosci 57, 104–110.
85. Onesto E, Colombrita C, Gumina V, Borghi MO, Dusi S, Doretti A, Fagiolari G, Invernizzi F, Moggio M, Tiranti V et al. (2016) Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. Acta Neuropathol Commun 4, 47.
86. Bartolome F, Esteras N, Martin-Requero A, Boutoleau-Bretonniere C, Vercelletto M, Gabelle A, Le Ber I, Honda T, Dinkova-Kostova AT, Hardy J et al. (2017) Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates. Sci Rep, 7, 1666.
87. Brunetti D, Dusi S, Morbin M, Uggetti A, Moda F, D'Amato I, Giordano C, d'Amati G, Cozzi A, Levi S et al. (2012) Pantothenate kinase-associated neurodegeneration: altered mitochondria membrane potential and defective respiration in Pank2 knock-out mouse model. Hum Mol Genet 21, 5294–5305.
88. Orellana DI, Santambrogio P, Rubio A, Yekhlef L, Cancellieri C, Dusi S, Giannelli SG, Venco P, Mazzara PG, Cozzi A et al. (2016) Coenzyme A corrects pathological defects in human neurons of PANK2-associated neurodegeneration. EMBO Mol Med 8, 1197–1211.
89. Arber C, Angelova PR, Wiethoff S, Tsuchiya Y, Mazzacuva F, Preza E, Bhatia KP, Mills K, Gout I, Abramov AY et al. (2017) iPSC-derived neuronal models of PANK2-associated neurodegeneration reveal mitochondrial dysfunction contributing to early disease. PLoS One 12, e0184104.
90. Wiethoff S and Houlden H (2017) Neurodegeneration with brain iron accumulation. Handb Clin Neurol 145, 157–166.
91. Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N et al. (2006) PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 38, 752–754.
92. Giri A, Guven G, Hanagasi H, Hauser AK, Erginul-Unaltuna N, Bilgic B, Gurvit H, Heutink P, Gasser T, Lohmann E et al. (2016) PLA2G6 mutations related to distinct phenotypes: a new case with early-onset parkinsonism. Tremor Other Hyperkinet Mov (NY) 6, 363.
93. Kinghorn KJ, Castillo-Quan JI, Bartolome F, Angelova PR, Li L, Pope S, Cocheme HM, Khan S, Asghari S, Bhatia KP et al. (2015) Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain 138, 1801–1816.
94. Abeti R, Parkinson MH, Hargreaves IP, Angelova PR, Sandi C, Pook MA, Giunti P and Abramov AY (2016) Mitochondrial energy imbalance and lipid peroxidation cause cell death in Friedreich's ataxia. Cell Death Dis 7, e2237.
95. Abeti R, Uzun E, Renganathan I, Honda T, Pook MA and Giunti P (2015) Targeting lipid peroxidation and mitochondrial imbalance in Friedreich's ataxia. Pharmacol Res 99, 344–350.
96. Quinti L, Dayalan NS, Trager U, Chen X, Kegel-Gleason K, Lleres D, Connolly C, Chopra V, Low C, Moniot S et al. (2017) KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proc Natl Acad Sci USA 114, E4676–E4685.
97. Quinti L, Casale M, Moniot S, Pais TF, Van Kanegan MJ, Kaltenbach LS, Pallos J, Lim RG, Naidu SD, Runne H et al. (2016) SIRT2- and NRF2-targeting thiazole-containing compound with therapeutic activity in Huntington's disease models. Cell Chem Biol 23, 849–861.